Kvartalsrapport (Q1)
70 dager siden‧31min
Ordredybde
Nasdaq Stockholm
Antall
Kjøp
940
Selg
Antall
100
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| 7 | - | - | ||
| 57 | - | - | ||
| 40 | - | - | ||
| 962 | - | - | ||
| 1 | - | - |
Høy
29,4VWAP
Lav
28,4OmsetningAntall
0,1 3 770
VWAP
Høy
29,4Lav
28,4OmsetningAntall
0,1 3 770
Meglerstatistikk
Mest nettokjøp
| Megler | Kjøpt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Anonym | 3 770 | 3 770 | 0 | 0 |
Mest nettosalg
| Megler | Kjøpt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Anonym | 3 770 | 3 770 | 0 | 0 |
Selskapshendelser
| Kommende | |
|---|---|
| 2025 Kvartalsrapport (Q2) | 15. juli |
| Historisk | ||
|---|---|---|
| 2024 Generalforsamling | 15. mai | |
| 2025 Kvartalsrapport (Q1) | 24. apr. | |
| 2024 Kvartalsrapport (Q4) | 6. feb. | |
| 2024 Kvartalsrapport (Q3) | 24. okt. 2024 | |
| 2024 Kvartalsrapport (Q2) | 16. juli 2024 |
Data hentes fra Millistream, Quartr
Kunder besøkte også
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
19. mai·Aksjene steg med 30 % midt i uken uten noen nyheter, noe som utløste spekulasjoner om private aksjer og drev aksjonærbasen, inkludert EQTs Thomas von Koch, Jan Ståhlberg og tidligere administrerende direktør Christian Kinch. https://nordicedge.substack.com/p/monday-morning-espresso-w2025
31. jan. 2022 · Endret31. jan. 2022 · EndretDet var jo ikke så godt med et tab på 9 mio kr med en omsætning på 55 mio. Hvor stor en omsætning skal der da til for at generere et overskud? Jeg har bemærket at omsætningen faktisk er vokset pænt år for år siden 2015, men kun ét år, er det lykkes at generere et lille overskud. De andre år har kørt med små underskud. Hvordan skal det så forstås, når VD skriver: " vi har skapat värdet för (..... ) og aktieägare"? Kursen er steget, ja, men indtjeningen i virksomheden har jo manglet, så den udmelding fra VD, synes jeg ikke om, når det omvendte er tilfældet. I givet fald er væksten på intern værdi i selskabet, men egenkapitalen er ikke steget. Jeg tror BAC skal have kigget på deres indtjening på produkterne eller evt. deres omkostningsniveau, for i mine øjne tjener de simpelt hen for lidt i.fht. en iøvrigt ret fin omsætning.
31. jan. 2022 · Endret31. jan. 2022 · EndretVad tror ni om följande konkurrens? https://www.svt.se/nyheter/lokalt/vast/chalmersforskare-bakom-coronadodande-uppfinning
31. jan. 2022 · Endret31. jan. 2022 · EndretIntressant delning, bra med alternativ. Tar några år att få i hop en organisation.
31. jan. 2022 · Endret31. jan. 2022 · EndretHydrocyn® aqua inactivates the coronavirus causing COVID-19 TUE, JUN 02, 2020 16:40 CET https://news.cision.com/bactiguard-holding-ab--publ-/r/hydrocyn--aqua-inactivates-the-coronavirus-causing-covid-19,c3126504 The effect of Hydrocyn® aqua (Hydrocyn) on the new coronavirus (SARS-CoV-2) causing COVID-19 has been confirmed. Tests performed by the Swedish National Veterinary Institute show that 99.9% of the virus particles were killed after exposure to Hydrocyn. Bactiguard launched Hydrocyn in the Swedish market in March, with focus on critical societal functions. In collaboration with the Swedish National Veterinary Institute (SVA), tests have been conducted with Hydrocyn on a viral culture of the new corona virus (SARS-CoV-2) that causes COVID-19. The result shows that 99.9% of the virus particles were inactivated – which means, they were no longer functional and thus not contagious. “The result is important in the fight against the spread of COVID-19. There is no vaccine yet and no effective COVID-19 drugs are available, so there is great need for effective prevention. Health care and the public need access to products that protect against the new coronavirus. We are therefore pleased that we have been able to prove that Hydrocyn is effective against this new virus and hope that we will soon be able to offer it to Swedish consumers,” says Stefan Grass, Bactiguard's Chief Medical Officer, MD PhD and formerly active as specialist physician in anesthesia and intensive care. “In addition to documented effects against coronavirus, Hydrocyn is also effective against bacteria and fungi. Unlike disinfectants based on, for example, alcohol, Hydrocyn is also kind to the body and does not cause irritation or tissue damage,” adds Stefan Grass. Bactiguard launched Hydrocyn in the Swedish market in mid-March and received customer orders, including from the Police Authority, in the first days after the launch, at a total value of just over SEK 20 million. This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-06-02, at. 16.40. For further information, please contact: Stefan Grass, Chief Medical Officer and Deputy CEO e-mail stefan.grass@bactiguard.se, mobile +46 707 25 24 48 Cecilia Edström, CEO, e-mail cecilia.edstrom@bactiguard.se, phone: +46 8 440 58 80 About Hydrocyn® aqua Bactiguard launched Hydrocyn® aqua in Sweden on March 12. Hydrocyn® aqua is an advanced disinfectant that is pH-neutral and water-based and can be used as a disinfectant solution for, for example, skin and surfaces. Unlike alcohol-based disinfectants, Hydrocyn® aqua is not irritating, toxic or harmful to the body. It is also not flammable. The active substance (HOCl) is a natural part of the human immune system. The product is CE marked (approved in the EU), registered by the US FDA and approved by the Swedish Chemicals Agency. About Bactiguard Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention. Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about how Bactiguard saves lives at www.bactiguard.com- deaktivert31. jan. 2022 · Endretdeaktivert31. jan. 2022 · EndretWoW! Dette kan bli stort!(masse tekst)! Coronakiller? Bactiguard Holding AB (publ): Bactiguard launches product that protects against Coronavirus Bactiguard launches HYDROCYN aqua®, a water-based product that has been proven to have a powerful effect on killing previous variants of coronavirus within 15-30 seconds. Previous experience shows that the proven effect can be transferred to new variants of coronavirus and tests on COVID-19 (SARS-CoV-2) are now underway at the Karolinska Institute to verify this."As a result of the rapid spread of COVID-19 in both Europe and the Middle East, we see a strong interest in HYDROCYN aqua, a water-based product that kills bacteria, fungi and virus in seconds without damaging or irritating the body. Many companies that want to work preventively to protect their employees have already contacted us and started placing orders," says Cecilia Edström, CEO. "Our mission is to prevent infections and save lives. Therefore, we want to roll out the product across all markets in our distribution network as quickly as possible, following the acquisition of Vigilenz. At the same time, we are working hard to increase production capacity to meet the growing demand from both hospitals and companies, especially since there is a shortage of disinfectants in many markets," continues Cecilia Edström. The effect of HYDROCYN aqua® on coronaviruses has been tested and it is documented that it kills 99.9 percent of previous variants within 15-30 seconds. Previous experience shows that the proven effect can be transferred to new variants of coronavirus and tests on COVID-19 (SARS-CoV-2) are now underway at the Karolinska Institute to verify this. HYDROCYN aqua® is a pH-neutral and water-based product that, unlike alcohol and chlorhexidine, isn't toxic or harmful to the body. The active substance is hypochlorous acid (HOCl). HYDROCYN aqua® is included in Bactiguard's portfolio of products following the acquisition of Vigilenz. Read more at www.hydrocynaqua.com. HYDROCYN aqua® is CE marked (EU approved) and FDA approved in the US. For further information, please contact: Cecilia Edström, CEO, phone +46 440 58 80 About Bactiguard Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Kvartalsrapport (Q1)
70 dager siden‧31min
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- 19. mai·Aksjene steg med 30 % midt i uken uten noen nyheter, noe som utløste spekulasjoner om private aksjer og drev aksjonærbasen, inkludert EQTs Thomas von Koch, Jan Ståhlberg og tidligere administrerende direktør Christian Kinch. https://nordicedge.substack.com/p/monday-morning-espresso-w2025
- 31. jan. 2022 · Endret31. jan. 2022 · EndretDet var jo ikke så godt med et tab på 9 mio kr med en omsætning på 55 mio. Hvor stor en omsætning skal der da til for at generere et overskud? Jeg har bemærket at omsætningen faktisk er vokset pænt år for år siden 2015, men kun ét år, er det lykkes at generere et lille overskud. De andre år har kørt med små underskud. Hvordan skal det så forstås, når VD skriver: " vi har skapat värdet för (..... ) og aktieägare"? Kursen er steget, ja, men indtjeningen i virksomheden har jo manglet, så den udmelding fra VD, synes jeg ikke om, når det omvendte er tilfældet. I givet fald er væksten på intern værdi i selskabet, men egenkapitalen er ikke steget. Jeg tror BAC skal have kigget på deres indtjening på produkterne eller evt. deres omkostningsniveau, for i mine øjne tjener de simpelt hen for lidt i.fht. en iøvrigt ret fin omsætning.
- 31. jan. 2022 · Endret31. jan. 2022 · EndretVad tror ni om följande konkurrens? https://www.svt.se/nyheter/lokalt/vast/chalmersforskare-bakom-coronadodande-uppfinning31. jan. 2022 · Endret31. jan. 2022 · EndretIntressant delning, bra med alternativ. Tar några år att få i hop en organisation.
- 31. jan. 2022 · Endret31. jan. 2022 · EndretHydrocyn® aqua inactivates the coronavirus causing COVID-19 TUE, JUN 02, 2020 16:40 CET https://news.cision.com/bactiguard-holding-ab--publ-/r/hydrocyn--aqua-inactivates-the-coronavirus-causing-covid-19,c3126504 The effect of Hydrocyn® aqua (Hydrocyn) on the new coronavirus (SARS-CoV-2) causing COVID-19 has been confirmed. Tests performed by the Swedish National Veterinary Institute show that 99.9% of the virus particles were killed after exposure to Hydrocyn. Bactiguard launched Hydrocyn in the Swedish market in March, with focus on critical societal functions. In collaboration with the Swedish National Veterinary Institute (SVA), tests have been conducted with Hydrocyn on a viral culture of the new corona virus (SARS-CoV-2) that causes COVID-19. The result shows that 99.9% of the virus particles were inactivated – which means, they were no longer functional and thus not contagious. “The result is important in the fight against the spread of COVID-19. There is no vaccine yet and no effective COVID-19 drugs are available, so there is great need for effective prevention. Health care and the public need access to products that protect against the new coronavirus. We are therefore pleased that we have been able to prove that Hydrocyn is effective against this new virus and hope that we will soon be able to offer it to Swedish consumers,” says Stefan Grass, Bactiguard's Chief Medical Officer, MD PhD and formerly active as specialist physician in anesthesia and intensive care. “In addition to documented effects against coronavirus, Hydrocyn is also effective against bacteria and fungi. Unlike disinfectants based on, for example, alcohol, Hydrocyn is also kind to the body and does not cause irritation or tissue damage,” adds Stefan Grass. Bactiguard launched Hydrocyn in the Swedish market in mid-March and received customer orders, including from the Police Authority, in the first days after the launch, at a total value of just over SEK 20 million. This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-06-02, at. 16.40. For further information, please contact: Stefan Grass, Chief Medical Officer and Deputy CEO e-mail stefan.grass@bactiguard.se, mobile +46 707 25 24 48 Cecilia Edström, CEO, e-mail cecilia.edstrom@bactiguard.se, phone: +46 8 440 58 80 About Hydrocyn® aqua Bactiguard launched Hydrocyn® aqua in Sweden on March 12. Hydrocyn® aqua is an advanced disinfectant that is pH-neutral and water-based and can be used as a disinfectant solution for, for example, skin and surfaces. Unlike alcohol-based disinfectants, Hydrocyn® aqua is not irritating, toxic or harmful to the body. It is also not flammable. The active substance (HOCl) is a natural part of the human immune system. The product is CE marked (approved in the EU), registered by the US FDA and approved by the Swedish Chemicals Agency. About Bactiguard Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention. Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about how Bactiguard saves lives at www.bactiguard.com
- deaktivert31. jan. 2022 · Endretdeaktivert31. jan. 2022 · EndretWoW! Dette kan bli stort!(masse tekst)! Coronakiller? Bactiguard Holding AB (publ): Bactiguard launches product that protects against Coronavirus Bactiguard launches HYDROCYN aqua®, a water-based product that has been proven to have a powerful effect on killing previous variants of coronavirus within 15-30 seconds. Previous experience shows that the proven effect can be transferred to new variants of coronavirus and tests on COVID-19 (SARS-CoV-2) are now underway at the Karolinska Institute to verify this."As a result of the rapid spread of COVID-19 in both Europe and the Middle East, we see a strong interest in HYDROCYN aqua, a water-based product that kills bacteria, fungi and virus in seconds without damaging or irritating the body. Many companies that want to work preventively to protect their employees have already contacted us and started placing orders," says Cecilia Edström, CEO. "Our mission is to prevent infections and save lives. Therefore, we want to roll out the product across all markets in our distribution network as quickly as possible, following the acquisition of Vigilenz. At the same time, we are working hard to increase production capacity to meet the growing demand from both hospitals and companies, especially since there is a shortage of disinfectants in many markets," continues Cecilia Edström. The effect of HYDROCYN aqua® on coronaviruses has been tested and it is documented that it kills 99.9 percent of previous variants within 15-30 seconds. Previous experience shows that the proven effect can be transferred to new variants of coronavirus and tests on COVID-19 (SARS-CoV-2) are now underway at the Karolinska Institute to verify this. HYDROCYN aqua® is a pH-neutral and water-based product that, unlike alcohol and chlorhexidine, isn't toxic or harmful to the body. The active substance is hypochlorous acid (HOCl). HYDROCYN aqua® is included in Bactiguard's portfolio of products following the acquisition of Vigilenz. Read more at www.hydrocynaqua.com. HYDROCYN aqua® is CE marked (EU approved) and FDA approved in the US. For further information, please contact: Cecilia Edström, CEO, phone +46 440 58 80 About Bactiguard Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Nasdaq Stockholm
Antall
Kjøp
940
Selg
Antall
100
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| 7 | - | - | ||
| 57 | - | - | ||
| 40 | - | - | ||
| 962 | - | - | ||
| 1 | - | - |
Høy
29,4VWAP
Lav
28,4OmsetningAntall
0,1 3 770
VWAP
Høy
29,4Lav
28,4OmsetningAntall
0,1 3 770
Meglerstatistikk
Mest nettokjøp
| Megler | Kjøpt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Anonym | 3 770 | 3 770 | 0 | 0 |
Mest nettosalg
| Megler | Kjøpt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Anonym | 3 770 | 3 770 | 0 | 0 |
Kunder besøkte også
Selskapshendelser
| Kommende | |
|---|---|
| 2025 Kvartalsrapport (Q2) | 15. juli |
| Historisk | ||
|---|---|---|
| 2024 Generalforsamling | 15. mai | |
| 2025 Kvartalsrapport (Q1) | 24. apr. | |
| 2024 Kvartalsrapport (Q4) | 6. feb. | |
| 2024 Kvartalsrapport (Q3) | 24. okt. 2024 | |
| 2024 Kvartalsrapport (Q2) | 16. juli 2024 |
Data hentes fra Millistream, Quartr
Kvartalsrapport (Q1)
70 dager siden‧31min
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Selskapshendelser
| Kommende | |
|---|---|
| 2025 Kvartalsrapport (Q2) | 15. juli |
| Historisk | ||
|---|---|---|
| 2024 Generalforsamling | 15. mai | |
| 2025 Kvartalsrapport (Q1) | 24. apr. | |
| 2024 Kvartalsrapport (Q4) | 6. feb. | |
| 2024 Kvartalsrapport (Q3) | 24. okt. 2024 | |
| 2024 Kvartalsrapport (Q2) | 16. juli 2024 |
Data hentes fra Millistream, Quartr
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- 19. mai·Aksjene steg med 30 % midt i uken uten noen nyheter, noe som utløste spekulasjoner om private aksjer og drev aksjonærbasen, inkludert EQTs Thomas von Koch, Jan Ståhlberg og tidligere administrerende direktør Christian Kinch. https://nordicedge.substack.com/p/monday-morning-espresso-w2025
- 31. jan. 2022 · Endret31. jan. 2022 · EndretDet var jo ikke så godt med et tab på 9 mio kr med en omsætning på 55 mio. Hvor stor en omsætning skal der da til for at generere et overskud? Jeg har bemærket at omsætningen faktisk er vokset pænt år for år siden 2015, men kun ét år, er det lykkes at generere et lille overskud. De andre år har kørt med små underskud. Hvordan skal det så forstås, når VD skriver: " vi har skapat värdet för (..... ) og aktieägare"? Kursen er steget, ja, men indtjeningen i virksomheden har jo manglet, så den udmelding fra VD, synes jeg ikke om, når det omvendte er tilfældet. I givet fald er væksten på intern værdi i selskabet, men egenkapitalen er ikke steget. Jeg tror BAC skal have kigget på deres indtjening på produkterne eller evt. deres omkostningsniveau, for i mine øjne tjener de simpelt hen for lidt i.fht. en iøvrigt ret fin omsætning.
- 31. jan. 2022 · Endret31. jan. 2022 · EndretVad tror ni om följande konkurrens? https://www.svt.se/nyheter/lokalt/vast/chalmersforskare-bakom-coronadodande-uppfinning31. jan. 2022 · Endret31. jan. 2022 · EndretIntressant delning, bra med alternativ. Tar några år att få i hop en organisation.
- 31. jan. 2022 · Endret31. jan. 2022 · EndretHydrocyn® aqua inactivates the coronavirus causing COVID-19 TUE, JUN 02, 2020 16:40 CET https://news.cision.com/bactiguard-holding-ab--publ-/r/hydrocyn--aqua-inactivates-the-coronavirus-causing-covid-19,c3126504 The effect of Hydrocyn® aqua (Hydrocyn) on the new coronavirus (SARS-CoV-2) causing COVID-19 has been confirmed. Tests performed by the Swedish National Veterinary Institute show that 99.9% of the virus particles were killed after exposure to Hydrocyn. Bactiguard launched Hydrocyn in the Swedish market in March, with focus on critical societal functions. In collaboration with the Swedish National Veterinary Institute (SVA), tests have been conducted with Hydrocyn on a viral culture of the new corona virus (SARS-CoV-2) that causes COVID-19. The result shows that 99.9% of the virus particles were inactivated – which means, they were no longer functional and thus not contagious. “The result is important in the fight against the spread of COVID-19. There is no vaccine yet and no effective COVID-19 drugs are available, so there is great need for effective prevention. Health care and the public need access to products that protect against the new coronavirus. We are therefore pleased that we have been able to prove that Hydrocyn is effective against this new virus and hope that we will soon be able to offer it to Swedish consumers,” says Stefan Grass, Bactiguard's Chief Medical Officer, MD PhD and formerly active as specialist physician in anesthesia and intensive care. “In addition to documented effects against coronavirus, Hydrocyn is also effective against bacteria and fungi. Unlike disinfectants based on, for example, alcohol, Hydrocyn is also kind to the body and does not cause irritation or tissue damage,” adds Stefan Grass. Bactiguard launched Hydrocyn in the Swedish market in mid-March and received customer orders, including from the Police Authority, in the first days after the launch, at a total value of just over SEK 20 million. This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-06-02, at. 16.40. For further information, please contact: Stefan Grass, Chief Medical Officer and Deputy CEO e-mail stefan.grass@bactiguard.se, mobile +46 707 25 24 48 Cecilia Edström, CEO, e-mail cecilia.edstrom@bactiguard.se, phone: +46 8 440 58 80 About Hydrocyn® aqua Bactiguard launched Hydrocyn® aqua in Sweden on March 12. Hydrocyn® aqua is an advanced disinfectant that is pH-neutral and water-based and can be used as a disinfectant solution for, for example, skin and surfaces. Unlike alcohol-based disinfectants, Hydrocyn® aqua is not irritating, toxic or harmful to the body. It is also not flammable. The active substance (HOCl) is a natural part of the human immune system. The product is CE marked (approved in the EU), registered by the US FDA and approved by the Swedish Chemicals Agency. About Bactiguard Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention. Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about how Bactiguard saves lives at www.bactiguard.com
- deaktivert31. jan. 2022 · Endretdeaktivert31. jan. 2022 · EndretWoW! Dette kan bli stort!(masse tekst)! Coronakiller? Bactiguard Holding AB (publ): Bactiguard launches product that protects against Coronavirus Bactiguard launches HYDROCYN aqua®, a water-based product that has been proven to have a powerful effect on killing previous variants of coronavirus within 15-30 seconds. Previous experience shows that the proven effect can be transferred to new variants of coronavirus and tests on COVID-19 (SARS-CoV-2) are now underway at the Karolinska Institute to verify this."As a result of the rapid spread of COVID-19 in both Europe and the Middle East, we see a strong interest in HYDROCYN aqua, a water-based product that kills bacteria, fungi and virus in seconds without damaging or irritating the body. Many companies that want to work preventively to protect their employees have already contacted us and started placing orders," says Cecilia Edström, CEO. "Our mission is to prevent infections and save lives. Therefore, we want to roll out the product across all markets in our distribution network as quickly as possible, following the acquisition of Vigilenz. At the same time, we are working hard to increase production capacity to meet the growing demand from both hospitals and companies, especially since there is a shortage of disinfectants in many markets," continues Cecilia Edström. The effect of HYDROCYN aqua® on coronaviruses has been tested and it is documented that it kills 99.9 percent of previous variants within 15-30 seconds. Previous experience shows that the proven effect can be transferred to new variants of coronavirus and tests on COVID-19 (SARS-CoV-2) are now underway at the Karolinska Institute to verify this. HYDROCYN aqua® is a pH-neutral and water-based product that, unlike alcohol and chlorhexidine, isn't toxic or harmful to the body. The active substance is hypochlorous acid (HOCl). HYDROCYN aqua® is included in Bactiguard's portfolio of products following the acquisition of Vigilenz. Read more at www.hydrocynaqua.com. HYDROCYN aqua® is CE marked (EU approved) and FDA approved in the US. For further information, please contact: Cecilia Edström, CEO, phone +46 440 58 80 About Bactiguard Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Nasdaq Stockholm
Antall
Kjøp
940
Selg
Antall
100
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| 7 | - | - | ||
| 57 | - | - | ||
| 40 | - | - | ||
| 962 | - | - | ||
| 1 | - | - |
Høy
29,4VWAP
Lav
28,4OmsetningAntall
0,1 3 770
VWAP
Høy
29,4Lav
28,4OmsetningAntall
0,1 3 770
Meglerstatistikk
Mest nettokjøp
| Megler | Kjøpt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Anonym | 3 770 | 3 770 | 0 | 0 |
Mest nettosalg
| Megler | Kjøpt | Solgt | Netto | Internt |
|---|---|---|---|---|
| Anonym | 3 770 | 3 770 | 0 | 0 |